Of note, BRCA1/2 germline mutational status is routinely evaluated for the selection of advanced breast cancer patients who may benefit from the poly-adenosine diphosphate–ribose polymerase (PARP) inhibitors olaparib and talazoparib [66]. This evidence concerns the gene BRCA1 and breast carcinoma.